AKBA · Akebia Therapeutics Inc
United States · RS rating 5 · As of 2026-10-14
| Price | 0.70 USD |
|---|---|
| 1-day change | -8.8% |
| RS rating (overall / 1M / 3M / 12M) | 5 / 10 / 5 / 7 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 25 / 15 / 24 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | -1.9% |
| Distance from 52-week high | +77.8% |
| Market cap (USD) | $383.1M |